Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 912 participants.

Also called NCT07092709

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 912 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07092709
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07092709. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-14 (actual); primary completion 2028-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users
Acronym
PEARL-DOAC
Condition
Acute Ischemic Stroke
Intervention (Drug)
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
Intervention (Drug)
Placebo
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (class: other)

Record details

Record id
cardio:ct-nct07092709
Content hash
ef49b1dfb5cc1148b600aee7da1a588a613549ff321446489c14d3fe477c2ad7